Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2/3 Study the Bispecific Antibody (BsAb), Glofitamab, Plus Chemoimmunotherapy in Newly Diagnosed and Relapsed Burkitt and High-Grade (Double Hit) B-Cell Lymphomas With MYC and BCL2 Rearrangements

NCT07724457 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07724457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07724457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2/3 Study the Bispecific Antibody (BsAb), Glofitamab, Plus Chemoimmunotherapy in Newly Diagnosed and Relapsed Burkitt and High-Grade (Double Hit) B-Cell Lymphomas With MYC and BCL2 Rearrangements
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
November 1, 2033
Enrollment
271 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent burkitt lymphoma, recurrent high grade b-cell lymphoma with myc and bcl2 rearrangements, refractory burkitt lymphoma, refractory high grade b-cell lymphoma with myc and bcl2 rearrangements